Please use this identifier to cite or link to this item:
|Title:||Mitral and tricuspid valve repair in hypereosinophilic syndrome.||Austin Authors:||Al-Kaisey, Ahmed M;Meher-Homji, Zaal;Hayward, Philip A R;Jones, Elizabeth F||Affiliation:||Department of Cardiology, Austin Health, Heidelberg, Victoria, Australia
Department of Cardiac Surgery, Austin Health, Heidelberg, Victoria, Australia
|Issue Date:||27-Jun-2019||metadata.dc.date:||2019-06-27||Publication information:||BMJ Case Reports 2019; 12(6): e228951||Abstract:||Hypereosinophilic syndrome (HES) is a rare systemic condition, defined as a persistently elevated eosinophil count associated with end organ damage and the absence of a primary cause. Cardiac involvement occurs in about 50% of patients with HES. Myocardial infiltration results in endomyocardial fibrosis, valve dysfunction and mural thrombus. The atrioventricular valves are almost always involved, resulting in regurgitation due to leaflet restriction, most commonly affecting the posterior mitral valve leaflet. Surgical management remains challenging in patients with HES with limited data on the choice of valve surgery. We describe the case of a 17-year-old woman with HES complicated by congestive cardiac failure secondary to severe mitral and tricuspid regurgitation. Because of refractory heart failure despite medical therapy, surgical mitral and tricuspid valve repair was performed, and an excellent 24-month outcome was achieved. We believe this is the first report of double valve repair in this rare condition.||URI:||http://ahro.austin.org.au/austinjspui/handle/1/21123||DOI:||10.1136/bcr-2018-228951||ORCID:||0000-0001-5174-1034||PubMed URL:||31253659||Type:||Journal Article||Subjects:||heart failure|
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 7, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.